Your browser doesn't support javascript.
loading
Successful Multidisciplinary Treatment, Including Atezolizumab Plus Bevacizumab Biological Therapy, for Multiple Hepatocellular Carcinomas Adjacent to Major Vessels: A Case Report.
Harada, Kei; Fujikawa, Takahisa; Uemoto, Yusuke; Aibe, Yuki.
Affiliation
  • Harada K; Surgery, Kokura Memorial Hospital, Kitakyushu, JPN.
  • Fujikawa T; Surgery, Kokura Memorial Hospital, Kitakyushu, JPN.
  • Uemoto Y; Surgery, Kokura Memorial Hospital, Kitakyushu, JPN.
  • Aibe Y; Gastroenterology, Kokura Memorial Hospital, Kitakyushu, JPN.
Cureus ; 16(2): e53997, 2024 Feb.
Article in En | MEDLINE | ID: mdl-38476801
ABSTRACT
Multiple hepatocellular carcinomas (HCCs) are currently being treated with multimodal therapy that includes liver resection and local therapy. Although the necessity of multimodal therapy for multiple HCCs is evident, treating them is extremely difficult due to the complex nature of multiple HCCs and the frequent occurrence of underlying liver damage. We encountered a case in which long-term tumor control was achieved through multidisciplinary treatment, including atezolizumab plus bevacizumab combination biological therapy. As in the current case, less-invasive surgical resection combined with radiofrequency ablation after a combination of biological therapy may be one of the preferred options for the treatment of initially unresectable multiple HCCs.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cureus Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cureus Year: 2024 Document type: Article